Andres Nascimento

Barcelona University. CIBERER ISCIII
Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 132 publications

Congenital muscular dystrophy phenotypes

Congenital muscular dystrophy phenotypes

Journal: Medicina

Published: August 27, 2026

Clinical pattern and evolution of Charcot-Marie-Tooth disease in pediatrics

Clinical pattern and evolution of Charcot-Marie-Tooth disease in pediatrics

Journal: Medicina

Published: August 27, 2026

Expanding the phenotypic spectrum of COL6-related diseases: Motor neuropathy-like and neuromyopathy associated with COL6A3 c.7447A>G.

Expanding the phenotypic spectrum of COL6-related diseases: Motor neuropathy-like and neuromyopathy associated with COL6A3 c.7447A>G.

Journal: Journal of neuromuscular diseases

Published: July 28, 2026

Nucleoside therapy for thymidine kinase 2 deficiency: Long-term outcomes from a Brazilian cohort.

Nucleoside therapy for thymidine kinase 2 deficiency: Long-term outcomes from a Brazilian cohort.

Journal: Journal of neuromuscular diseases

Published: May 20, 2026

Behavioral barriers in the management of spinal muscular atrophy: The role of procrastination, regret, and burnout.

Behavioral barriers in the management of spinal muscular atrophy: The role of procrastination, regret, and burnout.

Journal: PloS one

Published: February 18, 2026

Clinical Variability and Genotype-Driven Outcomes in CHRND-Related Congenital Myasthenic Syndrome.

Clinical Variability and Genotype-Driven Outcomes in CHRND-Related Congenital Myasthenic Syndrome.

Journal: European journal of neurology

Published: February 09, 2026

Immune-mediated polyneuropathies

Immune-mediated polyneuropathies

Journal: Medicina

Published: October 02, 2025

Neuromuscular diseases in pediatrics with specific treatments

Neuromuscular diseases in pediatrics with specific treatments

Journal: Medicina

Published: October 02, 2025

Disease burden of untreated thymidine kinase 2 deficiency: insights from a large patient dataset.

Disease burden of untreated thymidine kinase 2 deficiency: insights from a large patient dataset.

Journal: Brain communications

Published: September 15, 2025

Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.

Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.

Journal: Neurology and therapy

Published: September 10, 2025

Caregiver-reported Patient Experiences with Duchenne Muscular Dystrophy: Qualitative In-trial Interviews 1 Year After Delandistrogene Moxeparvovec in the Pivotal EMBARK Trial.

Caregiver-reported Patient Experiences with Duchenne Muscular Dystrophy: Qualitative In-trial Interviews 1 Year After Delandistrogene Moxeparvovec in the Pivotal EMBARK Trial.

Journal: Neurology and therapy

Published: August 22, 2025

Real-world data on spinal muscular atrophy in Spain: Insights from over 500 individuals in the CuidAME project.

Real-world data on spinal muscular atrophy in Spain: Insights from over 500 individuals in the CuidAME project.

Journal: Journal of neuromuscular diseases

Published: July 29, 2025

Showing 1-12 of 132

Last Updated: 09/26/2026